Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Schizophrenia

Mescaline for Schizophrenia

12 papers and 0 clinical trials exploring mescaline as a treatment for schizophrenia.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

12 papers
Open Accessmeta

‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

In a pre-registered meta-analysis of 8 PAT trials (548 patients) and 16 open‑label traditional antidepressant studies (9,751 patients), psychedelic-assisted therapy was not more effective than open‑label antidepressants on the 17‑item Hamilton Depression Rating Scale (difference 0.3 favouring tAD; 95% CI −1.39 to 1.98; p=0.73). This equal‑unblinding comparison emphasises that blinding integrity materially influences apparent treatment effects and that both PAT and tAD produced robust, clinically meaningful improvements.

Published
June 9, 2025
Journal
OSF Preprints
Authors
Williams, Z. J., Barnett, H., Szigeti, B.
Open Accessmeta

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

This systematic review (2024) and meta-analysis (s=131) examines the incidence of psychedelic-induced psychosis, focusing on individuals with schizophrenia. It finds an incidence of 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs, with 3.8% of UCT participants with schizophrenia developing long-lasting psychotic symptoms. It also reports that 13.1% of those with psychedelic-induced psychosis later developed schizophrenia.

Published
November 27, 2024
Journal
Molecular Psychiatry
Authors
Sabé, M., Sulstarova, A., Glangetas, A., De Pieri, M., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L., Seragnoli, F., Thorens, G., Zullino, D., Preller, K., Böge, K., Leucht, S., Correll, C. U., Solmi, M., Kaiser, S., Kirschner, M.
Paywallmeta

Research abuses against people of colour and other vulnerable groups in early psychedelic research

This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.

Published
July 12, 2021
Journal
Journal of Medical Ethics
Authors
Strauss, D., de la Salle, S., Sloshower, J. A., Williams, M. T.
Paywallindividual

Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.

This investigative article highlights how psychedelic-assisted psychotherapy was used and developed in the 1950s, mainly in Canada by Humphry Osmond. It concludes that the relative isolation of the hospital enabled the research/therapy to stay away from conventions and look for collaborators outside psychiatry.

Published
August 1, 2018
Journal
History of Psychology
Authors
Dyck, E., Farrell, P.
Open Accessmeta

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

This book chapter (2018) describes the history, physiological response to psychedelics, and signaling pathway activated by serotonin (5-HT) 2A receptors.

Published
January 1, 2017
Journal
Current Topics in Behavioral Neurosciences
Authors
López-Giménez, J. F., González-Maeso, J.
Open Accessindividual

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

In a double-session, within-subjects study of 20 healthy volunteers, intravenous LSD (75 µg) produced acute psychosis‑like symptoms alongside heightened mood but led to increased optimism and trait openness two weeks later without raising delusional thinking. The authors propose that 5‑HT2A‑mediated increases in cognitive flexibility produce transient emotional lability during intoxication and leave a mid‑term “loosened cognition” that supports improved psychological wellbeing.

Published
February 5, 2016
Journal
Psychological Medicine
Authors
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., Nutt, D. J.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Schizophrenia trials Full Mescaline profile Full Schizophrenia profile